Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1254 • 2012 ACR/ARHP Annual Meeting
In Treatment-Naive Early RA the Left Ventricular Function Is Correlated to CRP, Doctors Global and Anti-CCP Status
BB Løgstrup¹, LD Kristensen¹, A. Hedemann-Andersen² and Torkell Ellingsen³, ¹Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ²Department of Radiology, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ³Department of Internal Medicine, Diagnostic Centre Regional Hospital Silkeborg, 8600 Silkeborg, Denmark
Background/Purpose: The role of inflammation and anti-CCP status in the pathogenesis of cardiovascular disease in RA remains unclear. Previous studies have suggested that both disease…
Abstract Number: 1200 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies in Idiopathic Pulmonary Fibrosis Are Not Citrulline-Specific: Implications for the Pathogenesis of Rheumatoid Arthritis
Elena B. Lugli¹, Muslima Chowdhury¹, Peter J. Charles², Michael G. Crooks³, Simon P. Hart³, Patrick Venables¹ and Benjamin A. Fisher⁴, ¹Kennedy Institute of Rheumatology, Oxford University, London, United Kingdom, ²Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ³Castle Hill Hospital, Hull York Medical School, Cottingham, United Kingdom, ⁴Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The association of rheumatoid arthritis (RA) with smoking and silica exposure has led to the hypothesis that the lung is the site where RA autoimmunity…
Abstract Number: 1208 • 2012 ACR/ARHP Annual Meeting
Stable Synovial Fluid Phenotype for Anti Citrullinated-Protein Antibodies in Established Rheumatoid Arthritis
Vijay Joshua¹, Lena Israelsson², Lars Klareskog³, Anca Catrina¹ and Vivianne Malmström⁴, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Presence of anti citrullinated-protein antibodies (ACPA) in the peripheral blood of patients with rheumatoid arthritis is a validated disease biomarker. We have previously shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.